Give Pfizer, the giant drugmaker that employs hundreds in southeastern Connecticut, points for boldness and persistence: The company has bravely put “tax inversions” back in the headlines. Pfizer, which already holds roughly $140 billion overseas and is quite skillful at minimizing its taxes, is considering a deal that could move its legal tax headquarters from New York to Dublin, where it could save bundles more.